Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aged Skin Clear all
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 25, 2026, 6:53 AM EDT
Terminated Phase 1 Interventional Results available

Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)

NCT05457491
View directory record Official record
Conditions
Skin Aging
Interventions
Human platelet extract (cosmetic product), Vanicream Gentle Facial Cleanser, EltaMD UV Daily Broad-Spectrum SPF 40, EltaMD PM Therapy Facial Moisturizer, Vanicream Lite Lotion
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Time Restricted Eating on Cancer Risk

NCT05038137
View directory record Official record
Conditions
Pre-diabetes, Breast Cancer, Time Restricted Feeding
Interventions
Time restricted feeding, Control
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 67 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, PF-04965842, PF04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 25, 2026, 6:53 AM EDT
Recruiting Phase 3 Interventional

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Santa Monica, California • Miami, Florida • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Strength Training for Older Breast Cancer Survivors

NCT00591747
View directory record Official record
Conditions
Breast Neoplasm, Osteoporosis, Postmenopausal
Interventions
Resistance Exercise, Flexibility Training
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tolerability Study of the Application of a 3M Microstructure Transdermal System

NCT01257763
View directory record Official record
Conditions
Healthy
Interventions
Transdermal Microchannel Skin System, Sham device
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

NCT00619801
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years to 6 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00397579
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
DT388IL3
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Sorbent Therapy of the Cutaneous Porphyrias

NCT01422915
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
Colestipol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 25, 2026, 6:53 AM EDT
Active, not recruiting Phase 1 Interventional

'ADVANCE' (A Pilot Trial)

NCT03858322
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Cyclophosphamide, Carboplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 2 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

NCT00702507
View directory record Official record
Conditions
Diaper Rash
Interventions
0.25 % Miconazole Nitrate Ointment
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
Up to 15 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 25, 2026, 6:53 AM EDT
Enrolling by invitation Phase 3 Interventional

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin

NCT02090894
View directory record Official record
Conditions
Pre-cancerous Geriatric Skin
Interventions
UV Light (Laser Genesis)
Device
Lead sponsor
Indiana University
Other
Eligibility
65 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging

NCT06125912
View directory record Official record
Conditions
Skin Aging
Interventions
Dime Beauty TBT Cream, Positive Control
Other
Lead sponsor
Dime Beauty Co.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 25, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging

NCT07399028
View directory record Official record
Conditions
Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin
Interventions
Sculptra®
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 25, 2026, 6:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type

NCT01688063
View directory record Official record
Conditions
Skin Scarring, Skin Elasticity
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 6:53 AM EDT